Zepbound Canada: Cost, Dosing, and How It Compares to Mounjaro and Wegovy

In recent years, Canadians seeking tirzepatide for weight loss only had one option: an off-label prescription for Mounjaro, the diabetes brand of the medication. That changed in mid-2025, when Zepbound — the weight-management brand of tirzepatide — was approved by Health Canada.

The arrival of Zepbound in Canada follows a broader shift in how doctors view obesity. The Canadian Adult Obesity Clinical Practice Guidelines now frame obesity as a complex condition that warrants long-term medical management, rather than short-term lifestyle advice alone. Highly effective medications like Zepbound are now a central part of how long-term weight loss care is delivered in Canada.

This article covers what Zepbound is, how it compares to Mounjaro, Ozempic, and Wegovy, and what the Canadian label actually says about sleep apnea. We also break down Zepbound’s cost, dosing schedule, and side effects. 

What Is Zepbound?

Zepbound is a once-weekly injection used for long-term weight management. It is manufactured by Eli Lilly, and the active ingredient is tirzepatide — the same molecule sold under the brand name Mounjaro for type 2 diabetes.

What makes tirzepatide distinct from other weight loss injections is how it works. Drugs like Ozempic and Wegovy mimic a single gut hormone called GLP-1. Tirzepatide mimics two: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This “dual-agonist” effect appears to produce greater weight loss than targeting GLP-1 alone.

In Canada, Zepbound is approved as a long-term treatment for adults with obesity (BMI ≥30), or those who are overweight (BMI ≥27) and living with at least one weight-related health condition (including hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease). Guidelines state that Zepbound should be prescribed alongside a reduced-calorie diet and increased physical activity.

How Does Zepbound Work for Weight Loss?

Zepbound mimics GLP-1 and GIP, which are two incretin hormones released by the intestine after meals. These hormones work on overlapping but distinct parts of the body’s appetite and energy regulation system. 

Activating the GLP-1 receptor is known to:

• Slow gastric emptying
• Reduce hunger signals in the brain
• Enhance insulin secretion

The added GIP receptor activation from Zepbound appears to amplify these effects, and may also influence how the body stores and uses fat.

In practice, Zepbound weight loss occurs in a similar way to other GLP-1 medications. Food stays in the stomach longer after meals, hunger between meals is reduced, and many people report a noticeable drop in the persistent background thoughts about food.

How Much Weight Can You Lose on Zepbound?

In clinical trials, adults on the highest dose of Zepbound lost an average of roughly 21% of their body weight over 72 weeks. This is the largest average weight loss reported for any prescription medication currently approved in Canada for chronic weight management.

Below is a brief summary of the main research trials done with Zepbound and the weight loss results achieved. 

SURMOUNT-1 Trial Results

The main evidence for Zepbound comes from SURMOUNT-1, a phase 3 randomized trial of 2,539 adults with obesity or overweight (without type 2 diabetes), treated with tirzepatide (the active ingredient of Zepbound). 

Over 72 weeks, average weight loss was:

• 5 mg dose: 15.0% of body weight
• 10 mg dose: 19.5% of body weight
• 15 mg dose: 20.9% of body weight
• Placebo: 3.1% of body weight

About 91% of participants on the 15 mg Zepbound dose lost at least 5% of their body weight, and more than half lost 20% or more.

Long-Term Results

A three-year follow-up analysis of patients enrolled in the SURMOUNT trial confirmed the weight loss from Zepbound was sustained over 176 weeks, with an average weight loss of 19.7% after three years on the 15 mg dose. This analysis also found that treatment significantly reduced the rate of progression from prediabetes to type 2 diabetes.

What Happens If You Stop Taking Zepbound?

As with all GLP-1-based medications, the results from Zepbound largely depend on staying on the medication. Observational and trial data suggest most of the weight is regained if treatment is stopped. This is why Zepbound (like Wegovy, Ozempic, and Mounjaro) is considered a long-term therapy.

Is Zepbound Available in Canada?

Health Canada approved Zepbound on May 13, 2025, and Eli Lilly launched the medication at Canadian pharmacies on July 9, 2025. It is a prescription-only medication, which means patients need to consult with a licensed Canadian healthcare provider to determine whether it’s an appropriate treatment option for them.

In Canada, Zepbound is sold exclusively as the KwikPen — a multi-dose prefilled pen containing four weekly doses. This is a different format from the single-dose auto-injector pens Zepbound launched with in the United States.

Zepbound vs Mounjaro

Zepbound and Mounjaro contain the exact same active ingredient (tirzepatide), at the same doses, delivered in similar pens. The clinical effect is identical because the molecule is identical — but there is an important regulatory difference. 

Mounjaro is officially approved by Health Canada for type 2 diabetes, while Zepbound is approved for chronic weight management. Lilly markets them as separate brands so each can carry an indication-specific label, packaging, and patient support material.

In practice, Canadians with type 2 diabetes who want tirzepatide would typically be prescribed Mounjaro, while those pursuing weight loss without diabetes would be prescribed Zepbound.

What About “Off-Label” Mounjaro?

Before Zepbound’s approval, Canadians who wanted tirzepatide for weight loss relied on off-label prescriptions for Mounjaro. Off-label prescribing is a common and legal practice in Canada, where a licensed provider prescribes an approved medication for a use Health Canada has not specifically authorized. 

Zepbound’s approval gives weight-management patients an on-label option with the identical molecule. Private insurance plans that cover anti-obesity medications are more likely to reimburse Zepbound under their weight-management benefits, and Lilly’s patient support programs for Zepbound are built specifically around weight-management use.

Zepbound vs Ozempic: Are They the Same?

Zepbound (tirzepatide) and Ozempic (semaglutide) are different molecules made by different manufacturers. They are often grouped together in conversation as “GLP-1s,” but this comparison is imprecise.

While there is some overlap between how Zepbound and Ozempic work, there are several important differences to be aware of, including:

• Active ingredient: Zepbound contains tirzepatide, while Ozempic contains semaglutide — two distinct molecules.
• Mechanism: Zepbound is a dual agonist that activates both GLP-1 and GIP receptors. Ozempic is a GLP-1 receptor agonist only.
• Manufacturer: Zepbound is made by Eli Lilly; Ozempic is made by Novo Nordisk.
• Canadian indication: Zepbound is approved for chronic weight management. Ozempic is approved only for type 2 diabetes, so any prescription for weight loss is off-label — the on-label semaglutide option for weight management in Canada is Wegovy.
• Weight loss outcomes: Average weight loss on tirzepatide has been greater than on semaglutide in head-to-head trial data.

In short, Zepbound and Ozempic are part of the same broader drug class, but they are not interchangeable. The medications have different molecules, different mechanisms, and different approved uses in Canada.

Zepbound vs Wegovy

The most relevant head-to-head comparison for Canadians considering Zepbound is against Wegovy, the branded version of semaglutide approved for weight management. 

Both are once-weekly GLP-1-based injectables approved by Health Canada for weight management. However, there are some important differences between the medications that patients should be aware of.

We cover the main differences between Zepbound and Wegovy below. But as always, you should speak with a doctor to get advice based on your personal situation before deciding which one might be right for you.

SURMOUNT-5: The Head-to-Head Trial

The SURMOUNT-5 trial compared Zepbound and Wegovy directly over 72 weeks in 751 adults with obesity or overweight, without diabetes. 

Here are the key findings:

• Average weight loss: 20.2% on Zepbound vs 13.7% on Wegovy (roughly 47% more weight loss from Zepbound).
• Participants who lost 15% of body weight or more: 64.6% on Zepbound vs 40.1% on Wegovy.
• Participants who lost 25% of body weight or more: 31.6% on Zepbound vs 16.1% on Wegovy.
• Discontinuation due to side effects: 2.7% on Zepbound vs 5.6% on Wegovy.

To summarize, Zepbound produced greater weight loss than Wegovy across every threshold measured, with fewer participants stopping the medication because of side effects.

Where Wegovy Still Has an Edge

Greater weight loss does not automatically make Zepbound the right choice for every person. 

Here are a few things that work in Wegovy’s favour:

• Cardiovascular outcome data: The SELECT trial demonstrated that Wegovy reduced the risk of major adverse cardiovascular events in adults with obesity and established heart disease. Zepbound does not yet have equivalent outcome data, though trials are ongoing.
• Longer track record in Canada: Wegovy has been prescribed in Canada for longer than Zepbound, meaning both doctors and patients have more real-world familiarity with how it performs outside a clinical trial setting.
• Insurance coverage. Because Wegovy has been on the Canadian market longer, some private insurance plans have already worked out coverage pathways for it that may not yet exist for Zepbound. Generic versions of semaglutide (the active ingredient in Wegovy) are also expected in Canada on the nearby horizon, which may significantly reduce the cost of the medication.

Choosing Between Zepbound and Wegovy

There is no universally correct answer about whether Wegovy vs Zepbound is the best choice. 

The right fit always depends on an individual’s medical history, weight loss goals, susceptibility to side effects, cost, insurance coverage, and whether cardiovascular risk reduction is a specific treatment priority. In all cases, this decision should be made with a licensed healthcare provider who can review your full medical history and personal background.

Zepbound for Sleep Apnea: Does It Actually Work?

In the United States, the FDA has granted Zepbound a standalone approval for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Health Canada has not done the same. In Canada, OSA is listed as one of the qualifying weight-related conditions under the chronic weight management label — meaning a patient with OSA and a BMI of 27 or higher may qualify for Zepbound — but the approved use is weight management, not OSA treatment.

So what does the research say? The SURMOUNT-OSA trial found that participants on tirzepatide (the active ingredient in Zepbound) experienced roughly 25 fewer breathing interruptions per hour compared with placebo. Around 50% of participants met criteria for disease remission or reclassification to mild OSA after one year of treatment.

How Much Does Zepbound Cost in Canada?

Out-of-pocket, the price of Zepbound is typically $450 to $550 per month at Canadian retail pharmacies (depending on dose and dispensing fees). Provincial public drug plans generally do not cover anti-obesity medications, so most Canadians pay out-of-pocket for Zepbound or rely on private insurance. 

Private plans may cover Zepbound with prior authorization, typically requiring a BMI of 30 or higher (or 27 with a documented weight-related comorbidity). Benefits Canada reports that weight-management drugs are expected to be a major driver of private drug plan costs in 2026, reflecting how rapidly this category is expanding.

Eli Lilly Canada offers a patient support program, which can help eligible patients navigate private insurance coverage and reduce out-of-pocket Zepbound costs in Canada.

Zepbound Dosing

Zepbound uses a gradual dose increase schedule to give the body time to adjust and minimize gastrointestinal side effects. 

Here is the standard schedule for Zepbound dosing:

• Weeks 1–4: 2.5 mg once weekly (starter dose — not intended for weight loss, just adjustment)
• Weeks 5–8: 5 mg once weekly
• Further increases: 2.5 mg increments at intervals of at least 4 weeks, as needed for clinical response and tolerability
• Maximum dose: 15 mg once weekly

The slow increase exists because the most common side effects — nausea, diarrhea, constipation, vomiting — typically peak during dose increases. Most patients tolerate these increases better when they spend a full four weeks (or longer) at each level before moving up.

Zepbound Side Effects

As with other GLP-1 and GLP-1/GIP agonists, side effects of Zepbound are mostly gastrointestinal. 

The most commonly reported include:

• Nausea
• Diarrhea
• Constipation
• Vomiting
• Abdominal pain
• Decreased appetite
• Fatigue
• Injection-site reactions

Most Zepbound side effects are mild to moderate and tend to improve after a few weeks on a given dose. 

In SURMOUNT-1, discontinuation due to adverse events on the highest dose was around 6%, and the pattern of side effects was similar to what’s seen with other GLP-1-based weight loss treatments.

Tips for Managing Zepbound Side Effects

To reduce the likelihood of gastrointestinal discomfort from Zepbound, consider:

• Eating smaller and more frequent meals rather than large ones
• Avoiding greasy, fried, or heavily spiced foods (especially during dose increases)
• Staying well hydrated
• Eating slowly until you feel satisfied rather than full

These are the same strategies recommended for patients on Ozempic, Wegovy, and Mounjaro.

Serious Risks and Who Should Not Take Zepbound

More serious but less common risks from Zepbound include:

• Pancreatitis
• Gallbladder problems
• Kidney injury (usually linked to dehydration from vomiting or diarrhea)
• Severe allergic reactions

Zepbound carries a boxed warning for thyroid C-cell tumours based on rodent studies, and is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It’s also not recommended for people with a history of severe pancreatitis, active gallbladder disease, or severe gastroparesis, since the medication naturally slows stomach emptying.

Zepbound is also not recommended in pregnancy or while breastfeeding. Patients planning pregnancy should discuss timing with their provider well in advance, since the medication has a long half-life.

Frequently Asked Questions About Zepbound

Is Zepbound approved in Canada? 

Yes. Health Canada approved Zepbound on May 13, 2025, and it launched at Canadian pharmacies on July 9, 2025. It’s the first Health Canada–approved tirzepatide (the active ingredient of Zepbound and Mounjaro) specifically for chronic weight management.

What is Zepbound used for? 

In Canada, Zepbound is approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.

Zepbound cost in Canada without insurance? 

Out-of-pocket, Zepbound generally costs approximately $450 to $550 per month at Canadian retail pharmacies, depending on dose and dispensing fees.

How much is Zepbound in Canada with insurance? 

Private insurance plans that cover anti-obesity medications typically require prior authorization based on BMI and comorbidity criteria. Copays vary widely by plan. Provincial public drug plans generally do not cover Zepbound for weight management.

Is Zepbound the same as Ozempic? 

No. Zepbound is tirzepatide (a dual GIP/GLP-1 agonist) made by Eli Lilly. Ozempic is semaglutide (a GLP-1 agonist only) made by Novo Nordisk. Different molecules, different manufacturers, different mechanisms.

Is Zepbound the same as Mounjaro? 

Yes and no. Both contain tirzepatide at the same doses, but Mounjaro is approved in Canada for type 2 diabetes, while Zepbound is approved for chronic weight management.

How much weight can you lose on Zepbound? 

In the SURMOUNT-1 trial, adults without type 2 diabetes on the 15 mg dose of tirzepatide lost an average of about 20.9% of their body weight over 72 weeks, with sustained results confirmed at three years.

Zepbound Canada: Final Thoughts

Zepbound is one of the most effective weight loss medications available in Canada. But effectiveness alone doesn’t determine whether it’s the right fit for an individual. 

Medical history, current medications, BMI criteria, insurance coverage, cost, and side effects all factor into the decision about whether Zepbound is a suitable weight loss treatment. It’s also important to compare Zepbound against alternatives, like Wegovy or Contrave, which work through entirely different mechanisms.

A healthcare provider can help you evaluate whether Zepbound might be a suitable medication to support your weight loss goals. If Zepbound is appropriate, they can also guide you through starting the medication and monitoring long-term effectivness.

At Walk In, Canadian-licensed doctors are available for virtual consultations about weight loss treatments from the comfort of your home.

Speak With a Virtual Doctor About Weight Loss Treatment